0704 GMT - Fresenius Medical Care's better-than-expected results are solid but its U.S. dialysis treatment growth disappoints, Deutsche Bank analysts say in a note. The German dialysis company's closely watched underlying U.S. same-market treatment growth was flat due to a severe flu season leading to higher mortality among potential patients, the analysts say. Its backed outlook is a positive but foreign-currency exchanges should still put pressure on consensus earnings estimates, they say. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 03:06 ET (07:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.